254 related articles for article (PubMed ID: 15831812)
21. Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Frank JS; Grijalva VR; Ganesh VK; Mishra VK; Palgunachari MN; Fogelman AM
Circ Res; 2005 Sep; 97(6):524-32. PubMed ID: 16100046
[TBL] [Abstract][Full Text] [Related]
22. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide.
Datta G; Chaddha M; Hama S; Navab M; Fogelman AM; Garber DW; Mishra VK; Epand RM; Epand RF; Lund-Katz S; Phillips MC; Segrest JP; Anantharamaiah GM
J Lipid Res; 2001 Jul; 42(7):1096-104. PubMed ID: 11441137
[TBL] [Abstract][Full Text] [Related]
23. Haptoglobin binds the antiatherogenic protein apolipoprotein E - impairment of apolipoprotein E stimulation of both lecithin:cholesterol acyltransferase activity and cholesterol uptake by hepatocytes.
Cigliano L; Pugliese CR; Spagnuolo MS; Palumbo R; Abrescia P
FEBS J; 2009 Nov; 276(21):6158-71. PubMed ID: 19758344
[TBL] [Abstract][Full Text] [Related]
24. An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection.
Cormode DP; Briley-Saebo KC; Mulder WJ; Aguinaldo JG; Barazza A; Ma Y; Fisher EA; Fayad ZA
Small; 2008 Sep; 4(9):1437-44. PubMed ID: 18712752
[TBL] [Abstract][Full Text] [Related]
25. Biological properties of apolipoprotein a-I mimetic peptides.
Getz GS; Wool GD; Reardon CA
Curr Atheroscler Rep; 2010 Mar; 12(2):96-104. PubMed ID: 20425244
[TBL] [Abstract][Full Text] [Related]
26. A low-saturated-fat, low-cholesterol diet decreases plasma CETP activity and pre beta-HDL formation but does not affect cellular cholesterol efflux to plasma from type 1 diabetic patients.
De Vries R; Beusekamp BJ; Kerstens MN; Groen AK; Van Tol A; Dullaart RP
Scand J Clin Lab Invest; 2005; 65(8):729-37. PubMed ID: 16319046
[TBL] [Abstract][Full Text] [Related]
27. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice.
Navab M; Anantharamaiah GM; Hama S; Hough G; Reddy ST; Frank JS; Garber DW; Handattu S; Fogelman AM
Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1426-32. PubMed ID: 15845909
[TBL] [Abstract][Full Text] [Related]
28. Retention of α-helical structure by HDL mimetic peptide ATI-5261 upon extensive dilution represents an important determinant for stimulating ABCA1 cholesterol efflux with high efficiency.
Zheng Y; Patel AB; Narayanaswami V; Bielicki JK
Biochem Biophys Res Commun; 2013 Nov; 441(1):71-6. PubMed ID: 24129191
[TBL] [Abstract][Full Text] [Related]
29. Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein.
D'Souza W; Stonik JA; Murphy A; Demosky SJ; Sethi AA; Moore XL; Chin-Dusting J; Remaley AT; Sviridov D
Circ Res; 2010 Jul; 107(2):217-27. PubMed ID: 20508181
[TBL] [Abstract][Full Text] [Related]
30. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention.
Navab M; Anantharamaiah GM; Reddy ST; Fogelman AM
Nat Clin Pract Cardiovasc Med; 2006 Oct; 3(10):540-7. PubMed ID: 16990839
[TBL] [Abstract][Full Text] [Related]
31. Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptides.
Nayyar G; Mishra VK; Handattu SP; Palgunachari MN; Shin R; McPherson DT; Deivanayagam CCS; Garber DW; Segrest JP; Anantharamaiah GM
J Lipid Res; 2012 May; 53(5):849-858. PubMed ID: 22377531
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of lipid-binding properties of the N-terminal helical segments in human apolipoprotein A-I using fragment peptides.
Tanaka M; Tanaka T; Ohta S; Kawakami T; Konno H; Akaji K; Aimoto S; Saito H
J Pept Sci; 2009 Jan; 15(1):36-42. PubMed ID: 19048603
[TBL] [Abstract][Full Text] [Related]
33. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I.
Van Lenten BJ; Wagner AC; Jung CL; Ruchala P; Waring AJ; Lehrer RI; Watson AD; Hama S; Navab M; Anantharamaiah GM; Fogelman AM
J Lipid Res; 2008 Nov; 49(11):2302-11. PubMed ID: 18621920
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of apolipoprotein E secretion by macrophages in type 2 diabetic patients: role of HDL and apolipoprotein A-I.
Yamato K; Tamasawa N; Murakami H; Matsui J; Tanabe J; Suda T; Yasujima M
Diabetes Res Clin Pract; 2005 Aug; 69(2):124-8. PubMed ID: 16005361
[TBL] [Abstract][Full Text] [Related]
35. The apoA-I mimetic peptide 4F protects apolipoprotein A-I from oxidative damage.
White CR; Datta G; Wilson L; Palgunachari MN; Anantharamaiah GM
Chem Phys Lipids; 2019 Mar; 219():28-35. PubMed ID: 30707910
[TBL] [Abstract][Full Text] [Related]
36. Apolipoprotein A-I mimetic peptide reverses impaired arterial healing after injury by reducing oxidative stress.
Rosenbaum MA; Chaudhuri P; Abelson B; Cross BN; Graham LM
Atherosclerosis; 2015 Aug; 241(2):709-15. PubMed ID: 26125413
[TBL] [Abstract][Full Text] [Related]
37. Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects.
Plomgaard P; Dullaart RP; de Vries R; Groen AK; Dahlbäck B; Nielsen LB
J Intern Med; 2009 Sep; 266(3):258-67. PubMed ID: 19457058
[TBL] [Abstract][Full Text] [Related]
38. The unique role of apolipoprotein A-I in HDL remodeling and metabolism.
Pownall HJ; Ehnholm C
Curr Opin Lipidol; 2006 Jun; 17(3):209-13. PubMed ID: 16680023
[TBL] [Abstract][Full Text] [Related]
39. A Caucasian male with very low blood cholesterol and low apoA-II without evidence of atherosclerosis.
Park SH; Kim JR; Park JE; Cho KH
Eur J Clin Invest; 2007 Apr; 37(4):249-56. PubMed ID: 17373959
[TBL] [Abstract][Full Text] [Related]
40. The double jeopardy of HDL.
Navab M; Ananthramaiah GM; Reddy ST; Van Lenten BJ; Ansell BJ; Hama S; Hough G; Bachini E; Grijalva VR; Wagner AC; Shaposhnik Z; Fogelman AM
Ann Med; 2005; 37(3):173-8. PubMed ID: 16019715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
